In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altana Calls Trumps

Executive Summary

The success of gastrointestinal drug pantoprazole has turned mid-sized Altana into one of Europe's fastest growing pharmaceutical companies. By re-investing the proceeds from pantoprazole into its own R&D, Altana now has two late-stage follow-ons--ciclesonide and roflumilast--with similar potential to pantoprazole. Rather than simply out-licensing these compounds to larger players, Altana wants a more active role alongside its partners in marketing and selling its own drugs, hoping thereby to establish itself internationally.

You may also be interested in...



Pfizer Trims Altana From Pipeline

On July 1 Pfizer Inc. announced it was discontinuing development of Phase III COPD drug roflumilast (Daxas) and of Phase IIb HIV/AIDS drug capravirine, due to disappointing clinical results. The roflumilast decision highlights Pfizer's changing requirements and circumstances, as well as originator Altana's dependence on the compound.

Pfizer Trims Altana From Pipeline

On July 1 Pfizer Inc. announced it was discontinuing development of Phase III COPD drug roflumilast (Daxas) and of Phase IIb HIV/AIDS drug capravirine, due to disappointing clinical results. The roflumilast decision highlights Pfizer's changing requirements and circumstances, as well as originator Altana's dependence on the compound.

Altana Signs Up Pharmacia

Despite having little or no presence in the respiratory market, Pharmacia fought off Novartis, Roche and Aventis to win worldwide marketing right to Altana's roflumilast for COPD and asthma--a drug that could become a blockbuster. Altana reckons that Pharmacia, with no similar products of its own that might compete for attention, is strongly committed to roflumilast's success.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel